Stockreport

Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen [Yahoo! Finance]

Protalix BioTherapeutics, Inc. (DE)  (PLX) 
PDF Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) announced that the European Commission has approved a new dosing regimen for pegunigalsidase alfa for adults with Fa [Read more]